270 related articles for article (PubMed ID: 35653344)
21. The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma.
He L; Ren D; Lv G; Mao B; Wu L; Liu X; Gong L; Liu P
Cancer Med; 2023 Jan; 12(1):852-861. PubMed ID: 35621268
[TBL] [Abstract][Full Text] [Related]
22. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
[TBL] [Abstract][Full Text] [Related]
23. Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment.
Ding Q; Lin F; Huang Z; Li Y; Cai S; Chen X; Liu H; Qiu S
Sci Rep; 2024 Feb; 14(1):4426. PubMed ID: 38396056
[TBL] [Abstract][Full Text] [Related]
24. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
Front Immunol; 2022; 13():969034. PubMed ID: 36466881
[TBL] [Abstract][Full Text] [Related]
25. Identification of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma (HNSC) for the Exploration of Immunotherapy and Prognosis.
Huang C; Liu J
Genet Res (Camb); 2022; 2022():6880760. PubMed ID: 36636556
[TBL] [Abstract][Full Text] [Related]
26. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma.
Li Y; Liu H
Cancer Biomark; 2022; 34(3):359-374. PubMed ID: 35068446
[TBL] [Abstract][Full Text] [Related]
27.
Ge J; Jiang L; Tian Y; Zheng M; Huang M; Li J
J Int Med Res; 2020 Apr; 48(4):300060520919252. PubMed ID: 32517588
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of faciogenital dysplasias as biomarkers in head and neck squamous cell carcinoma.
Ma C; Li H; Li X; Lu S; He J
Biomark Med; 2019 Nov; 13(16):1399-1415. PubMed ID: 31596126
[No Abstract] [Full Text] [Related]
29. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma.
Takahashi H; Kawabata-Iwakawa R; Ida S; Mito I; Tada H; Chikamatsu K
Sci Rep; 2021 Sep; 11(1):17789. PubMed ID: 34493792
[TBL] [Abstract][Full Text] [Related]
30. Non-coding RNA-mediated high expression of
Chen K; Gong S; Fang X; Li Q; Ye M; Li J; Huang S; Zhao Y; Liu N; Li Y; Ma J
Front Immunol; 2022; 13():920136. PubMed ID: 36159813
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma.
He F; Chen Z; Deng W; Zhan T; Huang X; Zheng Y; Yang H
Int Immunopharmacol; 2021 Sep; 98():107789. PubMed ID: 34130150
[TBL] [Abstract][Full Text] [Related]
32. RCOR1 directly binds to MED28 and weakens its inducing effect on cancer stem cell-like activity of oral cavity squamous cell carcinoma cells.
Xiang Z; Zhou S; Liang S; Zhang G; Tan Y
J Oral Pathol Med; 2020 Sep; 49(8):741-750. PubMed ID: 32306431
[TBL] [Abstract][Full Text] [Related]
33. Constructing a prognostic model for head and neck squamous cell carcinoma based on glucose metabolism related genes.
Liu Y; Liu N; Zhou X; Zhao L; Wei W; Hu J; Luo Z
Front Endocrinol (Lausanne); 2023; 14():1245629. PubMed ID: 37876534
[TBL] [Abstract][Full Text] [Related]
34. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
35. Up-regulation of extracellular-matrix and inflammation related genes in oral squamous cell carcinoma.
Thakore VP; Patel KD; Vora HH; Patel PS; Jain NK
Arch Oral Biol; 2024 May; 161():105925. PubMed ID: 38442470
[TBL] [Abstract][Full Text] [Related]
36.
Wei Z; Shen Y; Zhou C; Cao Y; Deng H; Shen Z
Bioengineered; 2022 May; 13(5):13784-13800. PubMed ID: 35712757
[TBL] [Abstract][Full Text] [Related]
37. Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma.
Chai F; Zhang J; Fu T; Jiang P; Huang Y; Wang L; Yan S; Yan X; Yu L; Xu Z; Wang R; Xu B; Du X; Jiang Y; Zhang J
Channels (Austin); 2023 Dec; 17(1):2208928. PubMed ID: 37134043
[TBL] [Abstract][Full Text] [Related]
38. Arylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan-cancer.
Shen Y; Wei Z; Zhou C; Song J; Wang J; Wang J; Wu L; Fang S; Shen Z
J Clin Lab Anal; 2022 Sep; 36(9):e24600. PubMed ID: 35870182
[TBL] [Abstract][Full Text] [Related]
39. Identification of genetic mechanisms underlying lipid metabolism-mediated tumor immunity in head and neck squamous cell carcinoma.
Liu S; Wang S; Wang Z
BMC Med Genomics; 2023 May; 16(1):110. PubMed ID: 37210507
[TBL] [Abstract][Full Text] [Related]
40. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
